About this content About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical ...

智通财经APP获悉，周三美股盘前，雅培(ABT.US)公布了第四季度业绩。在医疗设备和营养部门表现强劲的推动下，该公司Q4营收实现超预期，不过，该公司提供的全年业绩不及市场预期，这导致该股盘前跌逾2%。 数据显示，雅培Q4营收同比增长1.5%至102.4亿美元，超过了分析师平均预期的101.86亿美元，不包括COVID-19检测相关的有机销售额增长了11%。调整后每股收益为1.19美元，与分析师预期一致。 按业务划分，医疗设备部门营收为44.4亿美元，同比增长17.5%，高于市场预期的43.3亿美元，其中，FreeStyle Libre连续血糖监测仪的销售额增长25.5%，与COVID检测相关的销售额为2.88亿美元，低于上年同期的10.7亿美元。 营养业务营收为20.4亿美元，同比增长12%。诊断业务营收为25.3亿美元，同比下降23%，与市场预期一致。仿制药业务销售额为12.2亿美元，同比增长0.5%，但低于市场预期的13.2亿美元;糖尿病护理销售额达到15.5亿美元，同比增长22%，高于预期的15.2亿美元。 在COVID检测业务急剧下降后，雅培希望重新将重心放在其核心领域，寻求通过其连续血糖监测仪等产 ...

Abbott实验室（NYSE: ABT）业绩表现 - Abbott第四季度盈利15.9亿美元，同比增长1.03亿美元[7] - 每股收益从59美分增至91美分，调整后的每股收益为1.19美元[7] - 营收同比增长2.0%，达到102.4亿美元，市场预期为每股1.19美元，营收101.9亿美元[7] Abbott未来展望 - Abbott预测2024财年销售额将增长10%，每股收益为4.50至4.70美元，分析师预计每股收益为4.63美元[2] Abbott股票表现 - Abbott股票目前支付1.93%的股息率，与10月中旬的低点相比仍上涨超过20%[3] Abbott销售情况 - Abbott的COVID销售额从去年的10.7亿美元急剧下降至2.88亿美元[8] - 医疗器械销售年化增长率为17.5%，有助于抵消COVID销售额的下降[8]

经济衰退时的安全避风港股票 - 专业金融分析师需要关注经济衰退时的安全避风港股票[1] - Intuit (INTU)作为税收和会计软件专家，是经济衰退时的安全避风港股票之一[7] - McDonald's (MCD)作为快餐巨头，具有稳定的盈利能力和股息增长记录，是经济衰退时的安全避风港股票之一[11] - Procter & Gamble (PG)作为消费品巨头，产品具有永久的需求，是经济衰退时的安全避风港股票之一[15] - Abbott Laboratories (ABT)作为医疗设备和保健公司，具有多样化的产品组合，是经济衰退时的安全避风港股票之一[19] - Walmart (WMT)作为大型零售商，提供一站式购物体验，是经济衰退时的安全避风港股票之一[23] - Sempra Energy (SRE)作为能源公司，服务于南加州市场，具有稳定的股息增长记录，是经济衰退时的安全避风港股票之一[27] - Philip Morris (PM)作为烟草公司，尽管传统吸烟率下降，但电子烟市场增长迅速，是经济衰退时的安全避风港股票之一[28]

Several expansive companies are expected to post stellar quarterly growth when they report Q4 earnings on Wednesday, January 24.Having a dominant presence in their respective markets here are a few top-rated Zacks stocks to consider as their quarterly results approach.The Progressive (PGR) : Home and auto insurance giant Progressive shouldn’t be overlooked ahead of its Q4 results with earnings projected to soar 58% to $2.38 per share versus $1.50 a share in the comparative quarter. Fourth quarter sales are ...

Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories (ABT) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Abbott Laboratories is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pr ...

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.19 per share, indicating an increase of 15.5% compared to the year-ago period. Analysts forecast revenues of $10.17 billion, representing an increase of 0.8% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.7% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company ...

Abbott's Volt™ Pulsed Field Ablation System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to target and treat tissue in the heart Abbott's Volt PFA System is designed to overcome limitations of first-generation PFA systems by providing physicians a clearer indication of contact between the Volt PFA Catheter and targeted tiss ...

Abbott’s (ABT) Established Pharmaceuticals Division (EPD) businesses are expected to grow in the coming quarters, banking on new launches. However, the business environment continues to be challenging globally. The stock carries a Zacks Rank #3 (Hold) currently.Abbott is expanding its Diagnostics business foothold (consisting of 24% of the company’s total revenues in the third quarter of 2023). Over the past few quarters, there has been a decline in demand for Abbott’s rapid diagnostic tests to detect COVID ...

营收表现 - 上一季度调整后每股收益为1.14美元，超出Zacks Consensus Estimate 3.64%[2] - Zacks Consensus Estimate预计ABT 2023年第四季度营收为101.4亿美元，较去年同期下降0.5%[14] - Zacks Consensus Estimate预计ABT 2023年第四季度每股收益为1.19美元，同比增长15.5%[15] 业务表现 - Established Pharmaceuticals部门在多个市场和治疗领域表现强劲，预计第四季度业绩也将如此[4] - 诊断部门的Core Lab Diagnostics在国内和国际市场均表现强劲，预计第四季度增长将受到全球例行诊断测试需求和血液输血测试业务的强劲复苏的推动[6] - 新的FDA批准的实验室自动化解决方案GLP系统Track可能有助于Abbott满足客户实验室运营的灵活性和可扩展性需求[7] - 分子诊断方面，公司最近为Alinity m系列诊断试剂添加了一种强大的FDA批准的癌症筛查工具，预计这些发展将有助于ABT的财务业绩[8] - 医疗器械部门在美国和国际市场均表现强劲，预计第四季度业绩将继续增长[9] - 营养部门的婴儿营养销售可能会因在美国婴儿配方业务中持续占据市场份额而激增[12] 风险预警 - 预计宏观经济挑战可能会影响公司2023年第四季度的收入[13]